Form D · Pharmaceuticals
Immunophotonics, Inc.
St. Louis, MO · CIK 0001490953
Offering snapshot reported Sep 4, 2026 · SEC filing
- Reported sold
- $10.1M Indefinite offering
- Investors reported
- 45 Form D · investor count
- Minimum accepted
- $100K Reported outside-investor minimum
- First sale
- Jul 14, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 4, 2026 | Initial | $10,147,612 | No comparison | 45 | SEC filing |
| Mar 15, 2024 | Initial | $1,516,746 | No comparison | 17 | SEC filing |
| Feb 14, 2023 | Initial | $3,452,576 | No comparison | 22 | SEC filing |
| Jan 21, 2015 | Initial | $2,487,487 | No comparison | 28 | SEC filing |
| Jun 28, 2011 | Initial | $100,123 | No comparison | 1 | SEC filing |
| May 12, 2010 | Initial | $550,000 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-596476
Raised using rolling closings with majority in a tranche that closed in late August 2026.
Source: Form D, filed Sep 4, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Luciano Alleruzzo | Director, Promoter |
| Lu Alleruzzo | Executive |
| Robert H. Arch | Executive |
| Shelly L. Bishop | Director |
| Charlie Bolten | Director |
| Wei Chen | Director, Promoter |
| Jacqueline Hess | Director |
| Tomas Hode | Director, Executive, Promoter |
| Alexander Michael Hurst | Executive |
| Peter A. Jenkins | Director |
| Jonathan Knowles | Director |
| Richard Levenson | Director |
| Robert E. Nordquist | Director |
| Bobby W. Sandage | Director |
| David Smoller | Director |
| Miguel M. Zubizarreta | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
4340 Duncan Ave., Suite 212
St. Louis, MO, 63110
Phone: 314-501-1919
St. Louis, MO, 63110
Phone: 314-501-1919